Key Takeaways
- Volume-led growth, margin normalization: Revenue grew 27% YoY on 18% volume growth, but PAT margin compressed to 14% as elevated chlor-alkali margins receded toward the guided ~28% level and new-plant depreciation kicked in.
- CPVC ramp is ahead of schedule: The plant hit 70% utilization in December, one quarter early, with all domestic pipe-maker approvals secured and an order book full through March of the next financial year.
- ECH ramp is behind schedule: Utilization was "very miniscule" because global demand is weak and Indian customers operate on calendar-year contracts; management now expects optimization in Q1 FY24, a delay of six months to a year.
- Phase 2 expansion signals confidence: A 45,000 TPA CPVC expansion was announced, targeting commissioning by Q4 FY24, betting that India's 50% share of global CPVC demand will absorb the added capacity.
- What to watch next quarter: Whether ECH contracts materialize from February/March as expected, the pace of CPVC's continued ramp toward full utilization, and whether the promised market pickup after Chinese New Year actually shows up in realizations.
CPVC: The Star Performer
- Ramp exceeded plan: CPVC reached 70% capacity utilization in December 2022, one quarter ahead of the original Q1 FY24 target, after securing approval from all Indian pipe makers.
- Sales concentrated in December: 70% of Q3 CPVC sales occurred in December alone, following major customer approvals, so the quarter did not capture a full three months of contribution.
- Phase 2 expansion announced: Capacity will increase to 75,000 TPA by adding 45,000 TPA, with commissioning targeted for Q4 FY24 and P&L contribution from FY25.
- Revenue potential at bottom-of-cycle prices: Phase 1 full-year revenue is expected at ~₹350 crores; Phase 1 plus Phase 2 combined at ~₹800 crores, assuming current prices which management describes as a "bottom out situation."
- Margins in line with company range: CPVC margins are expected within the broad 26% to 30% guided range.
- Demand anchored domestically: India accounts for 50% of global CPVC demand, and Epigral's CPVC is 100% domestic-focused, insulating it from export market softness.
Maulik Patel: "We are very confident in terms of the chemistry and the confidence in the team. And it is -- we are increasing based on the demand in India right now, India needs more CPVC and we have an experience of last six months and looking at the future of demand of CPVC, we feel that it is right time to expand."
ECH: The Delayed Promise
- Utilization was negligible in Q3: Most Indian customers operate on calendar-year contracts (January to December), so discussions only began in January 2023; global and domestic customers have since sent samples and trial orders, and the majority have granted approvals.
- Pharmaceutical approvals are the long pole: While most customer approvals are in hand, pharmaceutical-grade approvals take longer and remain in process.
- Demand weakness is structural and global: Indian epoxy resin manufacturers export heavily, and their export volumes decreased because infrastructure-related demand in the US and Europe is down; China demand is also low due to COVID policy.
- Optimization pushed to Q1 FY24: Management now expects to reach optimized utilization in Q1 FY24, a delay of six months to a year from the original timeline, contingent on global demand recovery.
- Contracts expected from February/March: Management is in discussions with all large players and expects both export and domestic contracts to start contributing from late Q4 or early Q1 FY24.
- Long-run export-domestic mix: The target is 50% domestic, 50% export over the long term.
- Pricing seen at a floor: ECH pricing is considered almost bottomed out at ₹120–125 per kg.
Milind Kotecha: "It has been delayed by maybe six months or a year's time till the time demand again pickups."
Margin & Profitability Dynamics
- PAT margin compressed to 14%: The decline from 17% in Q3 FY22 was driven by higher interest and depreciation from newly commissioned capacity (caustic soda, ECH, CPVC), not operational weakness.
- Operating margin is normalizing toward guidance: Prior quarters benefited from elevated chlor-alkali spreads; margins are now declining back toward the long-term guided level of around 28%, and management stated they "will not improve drastically from here."
- Inventory lag created QoQ pressure: Realizations moved down while raw material inventory was held at higher cost, compressing EBITDA; this lag typically normalizes within three to four months.
- Absolute EBITDA will still grow: Even at normalized margins, absolute EBITDA will increase as new products ramp and volumes grow; ROCE is expected to remain above FY22 levels.
- Renewable energy to provide tailwind: A wind-solar hybrid plant (26% equity stake, ₹22 crores invested) will supply power under a 15–20 year fixed-price contract, reducing average power cost for derivatives plants from end of Q4 FY23.
- 9M FY23 outperformance provides context: Sales up 55%, EBITDA up 60% with margin up 107 bps to 32.9%, and PAT up 80% versus full-year FY22, all achieved in nine months.
Milind Kotecha: "Margins will not improve drastically from here on what we have achieved in the last nine months. It will be in the range of what we have communicated in terms of guidance, which is around 28%."
Demand Environment & Market Outlook
- Caustic soda ECU held stable: Caustic prices declined but chlorine prices improved from negative to slightly positive, keeping ECU realizations at "plus or minus 5,000 level," up 2% YoY.
- Export market was soft for six months: Caustic soda exports to Europe declined as European demand itself fell; management expects improvement from February after Chinese New Year as Chinese domestic consumption increases.
- Chlorine situation is improving: PVC prices bottomed out last month and started moving upward, a major driver for chlorine globally; chlorine derivatives are expected to pick up from February 15.
- China reopening is the swing factor: If Chinese internal demand improves, the global supply-demand scenario can change overnight, impacting pricing and demand for all chemicals.
- Hydrogen peroxide demand is strong: Lower volumes in Q3 were due to a maintenance shutdown, not demand weakness; export opportunity from paper customers is elevated because European production is down.
- Chloromethane demand expected to improve: Raw material and finished goods prices are moving in tandem, and overall demand is expected to be good from Q4 onward.
Maulik Patel: "If China internal demand improved, the global any industry will change the supply-demand scenario overnight, and I think the situation changed in terms of the pricing in the globally in terms of demand also."
Strategic Direction & Capital Allocation
- Revenue mix shifting toward derivatives: Derivatives & Specialty segment revenue share increased to 31% from 25% in Q3 FY22; the target is 50% from chlor-alkali and 50% from value addition within two years.
- Internal chlorine consumption rising: Currently at ~65%, targeted to reach ~75% in two years after chlorotoluene and CPVC expansion, reducing exposure to merchant chlorine price volatility.
- Chlorotoluene value chain on track: First phase targeting 10–15 derivative products with ~₹300–350 crores revenue and minimum 25% ROCE; commissioning by Q4 FY24, contributing from FY25.
- Growth prioritized over deleveraging: Management's first priority is not to compromise on growth; debt repayment and dividends will follow from internal accruals as new capex starts contributing to cash flow.
- Debt levels expected to hold: Net debt-to-EBITDA improved to 1.3x from 2.4x in Q3 FY22 and is expected to hover around this range.
- No green hydrogen ambitions: The company has no plans to enter green hydrogen via water electrolysis; focus remains on chlor-alkali derivatives.
Maulik Patel: "And our focus is very clear that, we would like to grow in the next three years in the derivative side of chlor-alkali... we are planning 50% revenue will come from chlor-alkali, 50% will come from value addition and the downstream industry."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CPVC Phase 2 commissioning | Additional 45,000 TPA capacity online | Q4 FY24 |
| Chlorotoluene value chain commissioning | First phase of 10–15 derivative products online | Q4 FY24 |
| ECH optimized utilization | Reach optimized capacity utilization | Q1 FY24 |
| Caustic soda expanded capacity utilization | Reach optimum utilization of additional 1,06,000 TPA | End of Q4 FY23 |
| Revenue mix target | 50% chlor-alkali, 50% derivatives | Within two years |
| Internal chlorine consumption target | ~75% (from ~65% currently) | Within two years |
| Long-term EBITDA margin | 28% plus-or-minus two percentage points | Ongoing |
| Volume growth expectation | 15% to 20% annually, capex-driven | Annual |
| Revenue growth expectation | 25% to 30% year-on-year | Annual |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹538 cr, +27% YoY |
| Volume growth | 18% YoY |
| EBITDA | ₹167 cr, +18% YoY |
| EBITDA margin | 31%, vs 32.9% in 9M FY23 |
| PAT | ₹77 cr, +11% YoY |
| PAT margin | 14%, vs 17% in Q3 FY22 |
| 9M FY23 revenue | ₹1,626 cr, +55% YoY |
| 9M FY23 PAT | ₹277 cr, +80% YoY |
| Return on capital employed | 35% (9M FY23) |
| Return on equity | 46% (9M FY23), vs 36% in FY22 |
| Net debt to EBITDA | 1.3x, vs 2.4x in Q3 FY22 |
| Chlor-Alkali capacity utilization | 68% on expanded capacities |
| Chloromethane capacity utilization | 104% |
| Hydrogen Peroxide capacity utilization | 82% |
| CPVC capacity utilization | ~40% quarterly average, reached 70% in December 2022 |
| Derivatives & Specialty revenue share | 31% of revenue, vs 25% in Q3 FY22 |
| Caustic soda ECU realization | +2% YoY |
| Chloromethane sales realization | -33% YoY |
| Hydrogen Peroxide sales realization | +9% |
| Interim dividend | ₹2.5 per share, 25% on face value of ₹10 |